摘要
肝细胞癌(HCC)是全世界发病率和死亡率较高的肿瘤之一。由于肠道与肝脏有着密切而特殊的关系,肠道菌群可通过肠道与肝脏间的相互作用来影响慢性肝病,促进HCC的发生发展。本文着重介绍肠道菌群通过肠渗漏及MAMPs-Toll样受体、菌群失衡及其代谢产物、调节肿瘤微环境等方式促进HCC的发生发展。通过靶向肠道菌群,如抗生素杀灭有害菌群、拮抗剂抑制TLR、益生菌平衡失调菌群及FMT改善肠道菌群等为HCC的治疗提供新的策略。
Hepatocellular carcinoma(HCC)is one of the tumors with high morbidity and mortality in the world.Due to the close and special relationship between intestine and liver,gut microbiota can affect chronic liver disease and promote the occurrence and development of HCC through the interaction between intestine and liver.This article mainly introduces that gut microbiota promotes the occurrence and development of HCC through intestinal leakage and MAMPs Toll like receptors,imbalance of flora and its metabolites,and regulation of tumor microenvironment.Targeting gut microbiota,such as antibiotics to kill harmful flora,antagonists inhibiting TLR,probiotic imbalance of flora and FMT to improve gut microbiota,provides a new strategy for the treatment of HCC.
作者
殷鼎威(综述)
井杰(审校)
YIN Dingwei;JING Jie(Department of Oncology,No.903 Hospital of PLA Joint Logistic Support Force,Hangzhou 310013,China;Department of Laboratory Medicine,The First Affiliated Hospital of Naval Medical University)
出处
《实用肿瘤学杂志》
CAS
2023年第3期281-286,共6页
Practical Oncology Journal
关键词
肝细胞癌
肠道菌群
慢性肝病
肿瘤治疗
Hepatocellular carcinoma
Gut microbiota
Chronic liver disease
Tumor therapy
